Using RNA Therapies to Target Inherited Retinal Diseases
RARECast - A podcast by RARECast - Thursdays
Categories:
Daniel de Boer, CEO of ProQR Therapeutics, discusses the evolution of his company, its pipeline of antisense oligonucleotide therapies, and the advantage of this approach in treating rare eye diseases.
